
AI Spotlight on JNJ
Company Description
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide.The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand.It serves general public, retail outlets, and distributors.The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension.
This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use.Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand.This segment serves wholesalers, hospitals, and retailers.
The company was founded in 1886 and is based in New Brunswick, New Jersey.
Market Data
Last Price | 162.3 |
Change Percentage | 1.64% |
Open | 159.88 |
Previous Close | 159.68 |
Market Cap ( Millions) | 390757 |
Volume | 12252130 |
Year High | 168.85 |
Year Low | 140.68 |
M A 50 | 148.99 |
M A 200 | 154.32 |
Financial Ratios
FCF Yield | 4.62% |
Dividend Yield | 3.06% |
ROE | 19.87% |
Debt / Equity | 51.24% |
Net Debt / EBIDTA | 43.92% |
Price To Book | 5.46 |
Price Earnings Ratio | 27.77 |
Price To FCF | 21.64 |
Price To sales | 4.4 |
EV / EBITDA | 14.14 |
News
- Feb -21 - TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis
- Feb -21 - Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara
- Feb -19 - Johnson & Johnson (JNJ) Laps the Stock Market: Here's Why
- Feb -19 - AbbVie Vs. Johnson & Johnson: Graham Would Prefer The Consumer Healthcare Giant
- Feb -18 - Fast Money: CELH, SLV, EEM, JNJ
- Feb -18 - J&J begins crucial battle over $10 billion baby powder settlement
- Feb -18 - Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
- Feb -18 - Johnson & Johnson: Rich History Of Excellence Poised To Endure
- Feb -15 - J&J resumes US rollout of Varipulse heart device after investigation
- Feb -13 - Johnson & Johnson halts late-stage E.coli vaccine trial after poor results
- Feb -13 - New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases
- Feb -13 - J&J to discontinue E.coli vaccine candidate study
- Feb -12 - What's a Fair Price to Buy Johnson & Johnson Stock?
- Feb -11 - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
- Feb -09 - 2 Stocks to Buy if There Is a Market Crash in 2025
- Feb -08 - One 'Safer' Buy In 10 February Dogs Of The Dow
- Feb -08 - Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
- Feb -07 - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
- Feb -07 - 3 Ideal Buys In 63 January Fortune 500 Industry Leaders Wherein 57 Paid Dividends And 39 Tested As 'Safer'
- Feb -05 - My Top 5 Dividend-Paying Buy-And-Hold Stocks For 2025
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Innovative Medicine
Expected Growth : 3.5 %
What the company do ?
Innovative Medicine from Johnson & Johnson refers to the development of novel treatments and medicines that address unmet medical needs, improving patient outcomes and transforming healthcare.
Why we expect these perspectives ?
Increasing demand for personalized medicine, advancements in gene editing technologies, and growing investments in R&D are driving the growth of innovative medicines, addressing unmet medical needs and improving patient outcomes.
Segment n°2 -> MedTech
Expected Growth : 4.5 %
What the company do ?
MedTech from Johnson & Johnson is a segment focused on developing innovative medical devices and diagnostic solutions to improve healthcare outcomes.
Why we expect these perspectives ?
Growing demand for minimally invasive surgeries, increasing prevalence of chronic diseases, and advancements in medical technology are driving the growth of MedTech segment.
Johnson & Johnson Products
Product Range | What is it ? |
---|---|
Band-Aids | Adhesive bandages for wound care |
Acuvue Contact Lenses | Daily disposable contact lenses for vision correction |
Tylenol | Pain relief medication for headaches and fever reduction |
Motrin | Pain relief medication for arthritis and menstrual cramps |
Neutrogena Skincare | Skincare products for cleansing, moisturizing, and protecting the skin |
Depend Adult Incontinence Products | Adult incontinence products for bladder control |
Sudafed | Decongestant medication for relieving nasal congestion |
Zytiga | Medication for treating prostate cancer |
Xarelto | Medication for preventing stroke and blood clots |
Invega | Medication for treating schizophrenia and bipolar disorder |
Johnson & Johnson's Porter Forces
Threat Of Substitutes
Johnson & Johnson has a diverse product portfolio, which reduces the threat of substitutes. However, the company faces competition from generic and biosimilar products, which could erode its market share.
Bargaining Power Of Customers
Johnson & Johnson's customers, including hospitals and pharmacies, have limited bargaining power due to the company's strong brand reputation and diversified product offerings.
Bargaining Power Of Suppliers
Johnson & Johnson relies on a network of suppliers for raw materials and components. While the company has some bargaining power, suppliers of critical components may have some negotiating power.
Threat Of New Entrants
The pharmaceutical and medical device industries have high barriers to entry, including significant R&D investments and regulatory hurdles, which limits the threat of new entrants.
Intensity Of Rivalry
The pharmaceutical and medical device industries are highly competitive, with many established players vying for market share. Johnson & Johnson faces intense competition from companies like Pfizer, Merck, and Medtronic.
Capital Structure
Value | |
---|---|
Debt Weight | 29.90% |
Debt Cost | 4.63% |
Equity Weight | 70.10% |
Equity Cost | 6.68% |
WACC | 6.07% |
Leverage | 42.65% |
Johnson & Johnson : Quality Control
Johnson & Johnson passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
Company | Rational |
---|---|
MRK | Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas … |
GILD | Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, … |
BMY | Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, … |
ABBV | AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat … |
AMGN | Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇

Gilead Sciences
A-Score
1-Year Total Return ->
🥈

Bristol-Myers Squibb
A-Score
1-Year Total Return ->
🥉

J&J
A-Score
1-Year Total Return ->
4

Merck
A-Score
1-Year Total Return ->
5

AbbVie
A-Score
1-Year Total Return ->
6
